0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Methicillin-Resistant Staphylococcus Aureus Drugs Market by Primary Segmentation - Global Forecast to 2030- Product Image
Methicillin-Resistant Staphylococcus Aureus Drugs Market by Primary Segmentation - Global Forecast to 2030- Product Image
Sale

Methicillin-Resistant Staphylococcus Aureus Drugs Market by Primary Segmentation - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968650
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Methicillin-Resistant Staphylococcus Aureus Drugs Market grew from USD 2.21 billion in 2024 to USD 2.36 billion in 2025. It is expected to continue growing at a CAGR of 6.46%, reaching USD 3.22 billion by 2030.

Navigating the MRSA Drug Arena with Precision

The rise of methicillin‐resistant Staphylococcus aureus has underscored the urgent demand for innovative antimicrobial therapies. As traditional antibiotics lose efficacy against resilient strains, stakeholders face mounting pressure to develop and deploy next‐generation treatments. This executive summary lays the groundwork for understanding how scientific breakthroughs, regulatory environments, and market forces converge to shape the future of MRSA drug development.

This introduction presents key themes that resonate throughout the report: the evolving pipeline of novel compounds, the interplay between policy shifts and pricing strategies, and the nuances of global access. By establishing these foundational elements, readers gain clarity on why strategic foresight and data‐driven decision making are indispensable in navigating the competitive and complex MRSA landscape.

Emerging Therapeutic Innovations Redefining Treatment Approaches

The therapeutic landscape for MRSA drugs is undergoing a profound transformation driven by molecular innovations and patient‐centric delivery models. Recent approvals and late‐stage candidates demonstrate a shift toward lipoglycopeptides and lipopeptides that offer enhanced potency against resistant strains while reducing dosing frequency. Concurrently, the expansion of oral formulations promises to improve outpatient management and curb hospital stays, reflecting a growing emphasis on convenience and cost-efficiency.

Equally pivotal are evolving regulatory frameworks that streamline accelerated pathways for breakthrough antimicrobials. Agencies worldwide are adapting criteria to balance expedited patient access with rigorous safety evaluations. This regulatory fluidity, combined with heightened investment in R&D consortia and public‐private partnerships, is fostering a more collaborative ecosystem. As a result, developers are recalibrating clinical strategies to align with shifting approval standards and to capitalize on opportunities for label expansions and orphan drug incentives.

Assessing the Ripple Effects of 2025 US Tariff Adjustments

The 2025 adjustments to United States import tariffs have introduced new complexities for MRSA drug manufacturers and distributors. Increased duties on active pharmaceutical ingredients have elevated production costs, compelling companies to reassess sourcing strategies and negotiate alternative supply contracts. These cost pressures are cascading through the value chain, influencing pricing negotiations with payers and prompting a more vigilant approach to reimbursement models.

Moreover, tariff‐induced cost differentials have affected global competitiveness. Companies exporting from regions with lower trade barriers can achieve more favorable margins, intensifying competition in both domestic and international markets. In response, some firms are accelerating investments in local manufacturing facilities to mitigate tariff exposure and enhance supply chain resilience. This strategic pivot not only addresses immediate cost concerns but also positions manufacturers for long-term stability amid evolving trade policies.

Unveiling the Layers of Market Segmentation for Targeted Strategies

A nuanced understanding of market segmentation reveals critical avenues for targeted growth and resource allocation. Administration routes span intravenous modalities favored in acute care settings alongside burgeoning oral alternatives tailored for outpatient therapy, each demanding distinct manufacturing and clinical support frameworks. Within approval status, the dichotomy of approved agents versus pipeline candidates offers insights into near-term opportunities and future revenue streams; examining phase I through phase III assets highlights the maturation curve of innovative compounds poised for market entry.

Distribution channels encompass hospital pharmacy environments, which require robust logistics and inventory management, as well as retail pharmacy points of sale where patient adherence and education become paramount. Differentiating drug classes-ranging from glycopeptides to oxazolidinones-sheds light on therapeutic positioning, competitive intensity, and lifecycle management strategies. End users extend across ambulatory surgical centers, where rapid infection control is essential, to outpatient clinics and tertiary hospitals, each with unique procurement protocols and formulary considerations. Indications prioritized include bacteremia, endocarditis, pneumonia, and skin and soft tissue infections, reflecting both clinical burden and reimbursement priorities. By integrating these segmentation layers, stakeholders can craft interventions that directly address the needs of diverse care settings and patient populations.

Mapping Regional Dynamics Shaping the MRSA Drug Market Landscape

Regional dynamics exert a profound influence on MRSA drug adoption and commercial viability. In the Americas, robust reimbursement frameworks and high healthcare expenditure facilitate the uptake of premium therapies, yet market access negotiations remain rigorous and outcomes-based contracting increasingly shapes formulary placements. Latin American markets present both growth potential and pricing sensitivity, prompting tailored launch sequencing and tiered pricing approaches.

Europe, Middle East & Africa encompass heterogenous regulatory landscapes. Western Europe benefits from centralized approval mechanisms and well-established antimicrobial stewardship programs, while emerging markets in the Middle East and Africa offer untapped patient populations but require strategic partnerships to navigate fragmented distribution networks. Reimbursement criteria vary widely, necessitating data-driven health economic models and real-world evidence generation.

In Asia-Pacific, expanding healthcare infrastructure and rising per capita income are driving demand for novel MRSA therapies. Local manufacturing initiatives and generic competition exert downward pricing pressure, yet government incentives for innovative treatments can offset cost constraints. Balancing market penetration against pricing dynamics in each jurisdiction is critical for sustainable growth.

Strategic Moves and Competitive Positioning of Leading Drug Developers

Leading pharmaceutical and biotechnology companies are strategically aligning portfolios to fortify their presence in the MRSA arena. Multinational firms leverage deep pockets and global networks to advance late-stage candidates through regulatory channels, while specialized biotech players focus on differentiated mechanisms of action and niche indications. Recent collaborations between established companies and innovative start-ups have accelerated development timelines, merging clinical expertise with agile trial designs.

Competitive positioning hinges on the ability to demonstrate superior efficacy against resistant strains and to secure label expansions for broader indications. Firms with comprehensive antimicrobial platforms can exploit cross-selling opportunities and bundle value-added services, such as digital adherence tools and companion diagnostics. Concurrently, smaller companies are forging alliances with contract research organizations to optimize cost structures and expedite enrollment in pivotal trials. Monitoring patent expirations and lifecycle extension strategies further informs how each stakeholder intends to maintain or disrupt market share.

Strategic Imperatives for Leadership in a Shifting Market Environment

Industry leaders should prioritize acceleration of oral formulation research to meet shifting treatment paradigms and capitalize on outpatient care expansions. Establishing collaborative frameworks with regulatory authorities will facilitate streamlined approval pathways and early dialogue on trial designs, ensuring alignment with evolving requirements. In parallel, forging supply chain partnerships across low-tariff regions can mitigate the impact of import duties and enhance manufacturing agility.

Investment in health economic analyses and real-world evidence generation is paramount to substantiate value propositions for payers and providers. Companies must also cultivate regional market access strategies that balance price sensitivity with innovation incentives, tailoring launch models to specific reimbursement environments. Finally, fostering cross-sector alliances-spanning academic institutions, technology vendors, and patient advocacy groups-can unlock new avenues for rapid clinical adoption and improved patient outcomes.

Rigorous Methodology Underpinning Robust Market Intelligence

This research integrates qualitative interviews with key opinion leaders, senior executives, and clinical experts alongside secondary data from regulatory filings, company disclosures, and peer-reviewed literature. Quantitative modeling techniques were applied to dissect historical trends and correlate external drivers such as trade policies and regulatory reforms with market movements. Triangulation of proprietary survey responses and third-party databases ensures the validity and reliability of insights.

To capture the evolving pipeline landscape, assets in phase I through phase III were catalogued and evaluated for mechanism of action, clinical trial progress, and competitive differentiation. Regional pricing and reimbursement scenarios were analyzed using health technology assessment reports and real-world case studies. Collectively, this robust methodology underpins the strategic recommendations presented throughout the report, equipping decision makers with actionable intelligence.

Consolidating Insights to Drive Informed Decision Making

The battle against MRSA demands a convergence of scientific innovation, strategic foresight, and operational excellence. Synthesizing insights from therapeutic advancements, tariff impacts, segmentation analyses, regional nuances, and competitive dynamics offers a comprehensive roadmap for stakeholders. By leveraging these findings, organizations can navigate uncertainties, optimize resource allocation, and accelerate the delivery of lifesaving treatments.

Ultimately, the evolving MRSA drug market presents both challenges and opportunities. Stakeholders who proactively integrate data-driven insights with collaborative strategies will be best positioned to address resistant infections, enhance patient outcomes, and achieve sustainable growth in this critical therapeutic area.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Primary Segmentation
    • Administration Route
      • Intravenous
      • Oral
    • Approval Status
      • Approved
      • Pipeline
        • Phase I
        • Phase II
        • Phase III
    • Distribution Channel
      • Hospital Pharmacy
      • Retail Pharmacy
    • Drug Class
      • Glycopeptides
      • Lipoglycopeptides
      • Lipopeptides
      • Oxazolidinones
    • End User
      • Ambulatory Surgical Centers
      • Clinics
      • Hospitals
    • Indication
      • Bacteremia
      • Endocarditis
      • Pneumonia
      • Skin And Soft Tissue Infection
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Allergan plc
  • Johnson & Johnson
  • Novartis AG
  • Astellas Pharma Inc.
  • Theravance Biopharma, Inc.
  • Paratek Pharmaceuticals, Inc.
  • Melinta Therapeutics, Inc.
  • Tetraphase Pharmaceuticals, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Primary Segmentation
8.1. Introduction
8.2. Administration Route
8.2.1. Intravenous
8.2.2. Oral
8.3. Approval Status
8.3.1. Approved
8.3.2. Pipeline
8.3.2.1. Phase I
8.3.2.2. Phase II
8.3.2.3. Phase III
8.4. Distribution Channel
8.4.1. Hospital Pharmacy
8.4.2. Retail Pharmacy
8.5. Drug Class
8.5.1. Glycopeptides
8.5.2. Lipoglycopeptides
8.5.3. Lipopeptides
8.5.4. Oxazolidinones
8.6. End User
8.6.1. Ambulatory Surgical Centers
8.6.2. Clinics
8.6.3. Hospitals
8.7. Indication
8.7.1. Bacteremia
8.7.2. Endocarditis
8.7.3. Pneumonia
8.7.4. Skin and Soft Tissue Infection
9. Americas Methicillin-Resistant Staphylococcus Aureus Drugs Market
9.1. Introduction
9.2. United States
9.3. Canada
9.4. Mexico
9.5. Brazil
9.6. Argentina
10. Europe, Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Drugs Market
10.1. Introduction
10.2. United Kingdom
10.3. Germany
10.4. France
10.5. Russia
10.6. Italy
10.7. Spain
10.8. United Arab Emirates
10.9. Saudi Arabia
10.10. South Africa
10.11. Denmark
10.12. Netherlands
10.13. Qatar
10.14. Finland
10.15. Sweden
10.16. Nigeria
10.17. Egypt
10.18. Turkey
10.19. Israel
10.20. Norway
10.21. Poland
10.22. Switzerland
11. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Drugs Market
11.1. Introduction
11.2. China
11.3. India
11.4. Japan
11.5. Australia
11.6. South Korea
11.7. Indonesia
11.8. Thailand
11.9. Philippines
11.10. Malaysia
11.11. Singapore
11.12. Vietnam
11.13. Taiwan
12. Competitive Landscape
12.1. Market Share Analysis, 2024
12.2. FPNV Positioning Matrix, 2024
12.3. Competitive Analysis
12.3.1. Merck & Co., Inc.
12.3.2. Pfizer Inc.
12.3.3. Allergan plc
12.3.4. Johnson & Johnson
12.3.5. Novartis AG
12.3.6. Astellas Pharma Inc.
12.3.7. Theravance Biopharma, Inc.
12.3.8. Paratek Pharmaceuticals, Inc.
12.3.9. Melinta Therapeutics, Inc.
12.3.10. Tetraphase Pharmaceuticals, Inc.
13. ResearchAI
14. ResearchStatistics
15. ResearchContacts
16. ResearchArticles
17. Appendix
List of Figures
FIGURE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 10. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 12. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 18. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOGLYCOPEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY BACTEREMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ENDOCARDITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 60. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 61. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 62. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 69. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 108. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 109. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 110. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 111. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 116. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 117. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 118. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 119. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 132. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 133. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 134. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 135. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 140. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 141. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 142. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 143. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 145. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. SPAIN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 172. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 173. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 174. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 175. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 177. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. DENMARK METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 187. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 189. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 190. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 191. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 193. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. QATAR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 195. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 196. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 197. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 198. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 199. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 201. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. FINLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 219. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 221. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 222. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 223. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 225. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. EGYPT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 227. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 228. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 229. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 230. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 231. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 233. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. TURKEY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 243. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 244. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 245. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 246. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 247. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. NORWAY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 251. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 252. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 253. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 254. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PIPELINE, 2018-2030 (USD MILLION)
TABLE 255. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 257. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. POLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PRIMARY SEGMENTATION, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUR

Companies Mentioned

The companies profiled in this Methicillin-Resistant Staphylococcus Aureus Drugs market report include:
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Allergan plc
  • Johnson & Johnson
  • Novartis AG
  • Astellas Pharma Inc.
  • Theravance Biopharma, Inc.
  • Paratek Pharmaceuticals, Inc.
  • Melinta Therapeutics, Inc.
  • Tetraphase Pharmaceuticals, Inc.

Methodology

Methodology DOWNLOAD NOW

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.36 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.22 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report 2025 - Product Image

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
EUR$4,490USDGBP
Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
EUR$7,950USDGBP
Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2025 - Product Image

Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2025

  • Drug Pipelines
  • 100 Pages
  • Global
From
EUR$2,000USDGBP
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - Global Strategic Business Report - Product Image

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
EUR$5,850USDGBP
Methicillin-resistant Staphylococcus Aureus (MRSA) Testing Market 2024-2028 - Product Image

Methicillin-resistant Staphylococcus Aureus (MRSA) Testing Market 2024-2028

  • Report
  • 172 Pages
  • Global
From
EUR$2,500USDGBP

About the MRSA Drug Market

Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that is resistant to many antibiotics. As a result, it is a major cause of infections in hospitals and other healthcare settings. To combat this, the MRSA drug market has developed a range of treatments, including antibiotics, antiseptics, and vaccines. These drugs are designed to target the bacteria and reduce the risk of infection. The MRSA drug market is highly competitive, with a range of companies offering different treatments. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. These companies are constantly developing new treatments to combat the spread of MRSA and other infectious diseases. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more